Overview

Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer

Status:
Not yet recruiting

Trial end date:
2026-09-30

Target enrollment:

Participant gender:

Summary

This multicenter, single-arm trial will explore the efficacy and safety of liposomal irinotecan and capecitabine plus bevacizumab as second-line therapy in metastatic colorectal cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Harbin Medical University

Treatments:

Bevacizumab
Capecitabine
Irinotecan